These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 25278011)

  • 1. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
    Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
    J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
    Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
    J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer.
    Chu FM; Sartor O; Gomella L; Rudo T; Somerville MC; Hereghty B; Manyak MJ
    Eur J Cancer; 2015 Aug; 51(12):1555-69. PubMed ID: 26048455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbidopa enhances antitumoral activity of bicalutamide on the androgen receptor-axis in castration-resistant prostate tumors.
    Thomas C; Wafa LA; Lamoureux F; Cheng H; Fazli L; Gleave ME; Rennie PS
    Prostate; 2012 Jun; 72(8):875-85. PubMed ID: 22072572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis.
    Lin TH; Lee SO; Niu Y; Xu D; Liang L; Li L; Yeh SD; Fujimoto N; Yeh S; Chang C
    J Biol Chem; 2013 Jul; 288(27):19359-69. PubMed ID: 23687298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
    Liu C; Armstrong CM; Lou W; Lombard AP; Cucchiara V; Gu X; Yang JC; Nadiminty N; Pan CX; Evans CP; Gao AC
    Mol Cancer Ther; 2017 Aug; 16(8):1521-1530. PubMed ID: 28500234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
    Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
    Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
    Laufer M; Sinibaldi VJ; Carducci MA; Eisenberger MA
    Urology; 1999 Oct; 54(4):745. PubMed ID: 10754148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
    Zhu Y; Liu C; Armstrong C; Lou W; Sandher A; Gao AC
    Clin Cancer Res; 2015 Sep; 21(18):4133-42. PubMed ID: 25995342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of quality of life in patients with previously untreated advanced prostate cancer receiving maximum androgen blockade therapy or LHRHa monotherapy: a multicenter, randomized, double-blind, comparative study.
    Arai Y; Akaza H; Deguchi T; Fujisawa M; Hayashi M; Hirao Y; Kanetake H; Naito S; Namiki M; Tachibana M; Usami M; Ohashi Y
    J Cancer Res Clin Oncol; 2008 Dec; 134(12):1385-96. PubMed ID: 18491137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone Pain and Survival Among Patients With Metastatic, Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG-1216 Trial.
    Gebrael G; Jo Y; Swami U; Plets M; Hage Chehade C; Narang A; Gupta S; Myint ZW; Sayegh N; Tangen CM; Hussain M; Dorff T; Lara PN; Lerner SP; Thompson I; Agarwal N
    JAMA Netw Open; 2024 Jul; 7(7):e2419966. PubMed ID: 38980676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.
    Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A
    Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
    See WA; Tyrrell CJ;
    J Cancer Res Clin Oncol; 2006 Aug; 132 Suppl 1():S7-16. PubMed ID: 16896884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
    Carpenter V; Saleh T; Min Lee S; Murray G; Reed J; Souers A; Faber AC; Harada H; Gewirtz DA
    Biochem Pharmacol; 2021 Nov; 193():114765. PubMed ID: 34536356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced androgen receptor signaling correlates with the androgen-refractory growth in a newly established MDA PCa 2b-hr human prostate cancer cell subline.
    Hara T; Nakamura K; Araki H; Kusaka M; Yamaoka M
    Cancer Res; 2003 Sep; 63(17):5622-8. PubMed ID: 14500404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.
    Chuu CP; Kokontis JM; Hiipakka RA; Fukuchi J; Lin HP; Lin CY; Huo C; Su LC; Liao S
    Cancer Sci; 2011 Nov; 102(11):2022-8. PubMed ID: 21781227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease.
    Scher HI; Liebertz C; Kelly WK; Mazumdar M; Brett C; Schwartz L; Kolvenbag G; Shapiro L; Schwartz M
    J Clin Oncol; 1997 Aug; 15(8):2928-38. PubMed ID: 9256137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: long-term follow-up of the SPCG-6 study.
    Thomsen FB; Brasso K; Christensen IJ; Johansson JE; Angelsen A; Tammela TL; Iversen P;
    Eur J Cancer; 2015 Jul; 51(10):1283-92. PubMed ID: 25892647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy.
    Teoh JY; Tsu JH; Yuen SK; Chiu PK; Chan SY; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
    Asian J Androl; 2017; 19(1):98-102. PubMed ID: 26585698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.